World ADC San Diego 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Daiichi Sankyo at World ADC San Diego 2026

Oct 12–15, 2026 San Diego, CA ~1.3k attendees Website

Daiichi Sankyo takes part in 6 sessions at World ADC San Diego 2026 in San Diego. Its sessions centre on clinical strategy for ADCs, from managing side effects to sequencing and combining treatments. The most concrete case is trastuzumab deruxtecan's move from late-line to first-line use in HER2-positive breast cancer, alongside early work on DS-3939a, an ADC aimed at TA-MUC1.

Organization	World ADC San Diego 2026 Attendance
Daiichi Sankyo Tokyo, Japan
daiichisankyo.com Large pharma Japanese pharmaceutical company behind the DXd ADC platform, including trastuzumab deruxtecan and datopotamab deruxtecan.	Panel Mon Oct 12 2:30pm Tackling Opportunities & Strategies to Identify High Risk Patients & Best Mitigate Clinical ADC Toxicities VIRTUAL PRESENTATION Pre-conference: 7th Toxicity Day Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Iksuda Therapeutics, Pfizer +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 2:30pm The Transition of an ADC From Late-Line to First-Line Therapy in HER2+ Breast Cancer & Earlier Line Gastric Cancer: The Trastuzumab Deruxtecan (T-DXd) Example Clinical Lessons Panel Tue Oct 13 3:30pm Assessing the Growing Importance of ADC Sequencing & Combination Approaches to Optimize Differentiated Clinical Performance Clinical Lessons Talk Wed Oct 14 2:00pm Highlighting Preclinical Development of DS-3939a, a DXd-ADC Targeting TA-MUC1 Preclinical Workshop Thu Oct 15 1:00pm Breaking Down Clinical Characterization & Differentiation Strategies to Set Up ADC Development for Success in an Increasingly Busy Oncology Landscape Post-conference workshop for Translational Medicine & Clinical Lessons · with NEOK Bio

Organization

World ADC San Diego 2026 Attendance

Daiichi Sankyo

Tokyo, Japan

daiichisankyo.com

Large pharma

Japanese pharmaceutical company behind the DXd ADC platform, including trastuzumab deruxtecan and datopotamab deruxtecan.

Panel

Mon Oct 12
2:30pm

Tackling Opportunities & Strategies to Identify High Risk Patients & Best Mitigate Clinical ADC Toxicities VIRTUAL PRESENTATION

Pre-conference: 7th Toxicity Day

Panel

Tue Oct 13
8:00am

Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact

Plenary · with Amgen, Iksuda Therapeutics, Pfizer +1 more

ADC discovery chemistryADC discovery biology

Talk

Tue Oct 13
2:30pm

The Transition of an ADC From Late-Line to First-Line Therapy in HER2+ Breast Cancer & Earlier Line Gastric Cancer: The Trastuzumab Deruxtecan (T-DXd) Example

Clinical Lessons

Panel

Tue Oct 13
3:30pm

Assessing the Growing Importance of ADC Sequencing & Combination Approaches to Optimize Differentiated Clinical Performance

Clinical Lessons

Talk

Wed Oct 14
2:00pm

Highlighting Preclinical Development of DS-3939a, a DXd-ADC Targeting TA-MUC1

Preclinical

Workshop

Thu Oct 15
1:00pm

Breaking Down Clinical Characterization & Differentiation Strategies to Set Up ADC Development for Success in an Increasingly Busy Oncology Landscape

Post-conference workshop for Translational Medicine & Clinical Lessons · with NEOK Bio

Instantly find 20 buyers from Daiichi Sankyo

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by World ADC or its organizers. Submit a correction